KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.

François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, Xavier Paoletti, Domenica Lorusso, Chel Hun Choi, Kosei Hasegawa, David Shao Peng Tan, Emma Hudson, Alison Davis, Germana Tognon, Stéphanie Lheureux, Mehmet Ali Vardar Key, Jean Emmanuel Kurtz, Jerome Alexandre, Florence Joly

Future Oncol 21(13) 1613-1623

PMID40323277
PMCIDPMC12140448
DOI10.1080/14796694.2025.2496133
发表日期2025-05-05
摘要

摘要

Immunotherapy (IO) in endometrial cancer (EC) is the standard of care in the second line setting in combination with an anti-angiogenic agent. Randomized clinical trials have reported results supporting the addition of IO to chemotherapy (paclitaxel plus carboplatin) in the first-line setting in advanced EC patients in the global population, with high efficacy in mismatch repair deficient (MMRd) patients. These trials were not designed to answer this de-escalation question in the MMRd population, who benefit greatly from IO.The international, randomized phase III, DOMENICA trial compares first-line dostarlimab versus chemotherapy alone (with planned cross-over) for advanced MMRd EC. Our primary endpoint will be progression-free survival. The key secondary endpoints will be overall survival, safety and quality of life [NCT05201547].

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。